nDatalyze Corp (TSE:NDAT)
:NDAT
Top Page
nDatalyze Corp
(NDAT)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.06
▲(215.00% Upside)
Action:ReiteratedDate:04/03/26
The score is primarily constrained by very weak financial performance (revenue collapse, persistent losses, and ongoing cash burn with equity erosion). Technicals are mixed and provide only limited support, while valuation is unfavorable due to negative earnings and no dividend data.
Positive Factors
Debt-free balance sheet
A zero-debt structure materially reduces solvency risk and gives management flexibility to fund operations or strategic initiatives without immediate interest burden. Over 2-6 months this lower fixed-cost profile preserves optionality for financing, partnerships, or restructuring while cash burn is addressed.
Negative Factors
Revenue collapse
A multi-year, near-total revenue decline erodes the company’s ability to leverage fixed costs and sustain critical operations. Over months this structural revenue failure undermines partner confidence, limits reinvestment capacity, and makes achieving break-even or scaling the subscription model materially more difficult without a clear demand turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt structure materially reduces solvency risk and gives management flexibility to fund operations or strategic initiatives without immediate interest burden. Over 2-6 months this lower fixed-cost profile preserves optionality for financing, partnerships, or restructuring while cash burn is addressed.
Read all positive factors
nDatalyze Corp (NDAT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$3.72M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.07
Revenue Growth-100.00%
EPS Growth65.85%
CountryCA
Employees1
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding41,327,423
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)6.95
Price to Sales (P/S)60.55
P/FCF Ratio-26.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
nDatalyze Corp Business Overview & Revenue Model
Company Description
nDatalyze Corp. generates technology-based health-related solutions. It is developing a machine-learning based online consumer mental health application and database licensing. The company also engages in the manufacture and sale of essential oil ...
How the Company Makes Money
nDatalyze Corp. generates revenue primarily through the licensing and subscription model of its software tools and platforms. These platforms provide organizations, healthcare providers, and individuals with valuable insights into mental health da...
nDatalyze Corp Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | Feb 2021 | Feb 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 887.00 | 1.71K | 96.34K | 171.22K | 424.93K | 662.77K |
| Gross Profit | -207.00 | 1.55K | 67.39K | 44.84K | 229.98K | 376.73K |
| EBITDA | -385.56K | -636.00K | -429.24K | -1.23M | -1.17M | -688.51K |
| Net Income | -387.41K | -554.48K | -155.60K | -1.23M | -1.17M | -698.53K |
Balance Sheet | ||||||
| Total Assets | 525.52K | 560.64K | 877.91K | 862.01K | 1.71M | 872.95K |
| Cash, Cash Equivalents and Short-Term Investments | 499.07K | 522.96K | 794.10K | 742.74K | 1.60M | 781.39K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 23.34K | 24.48K | 38.26K | 289.27K | 81.42K | 71.87K |
| Stockholders Equity | 502.18K | 536.16K | 839.65K | 572.74K | 1.63M | 801.08K |
Cash Flow | ||||||
| Free Cash Flow | -351.19K | -466.14K | -221.64K | -1.03M | -1.14M | 18.90K |
| Operating Cash Flow | -351.19K | -466.14K | -217.46K | -1.02M | -1.13M | 20.75K |
| Investing Cash Flow | 0.00 | 0.00 | -4.17K | -4.39K | -13.85K | -1.84K |
| Financing Cash Flow | 0.00 | 194.99K | 273.00K | 175.54K | 1.95M | 168.00K |
nDatalyze Corp Technical Analysis
Positive
0.02
Price Trends
0.06
Positive
0.04
Positive
0.03
Positive
Market Momentum
<0.01
Positive
53.22
Neutral
30.16
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NDAT, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.06, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.22 is Neutral, neither overbought nor oversold. The STOCH value of 30.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NDAT.
nDatalyze Corp Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$441.99M | 90.72 | 2.75% | ― | 59.34% | -23.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$52.68M | -2.31 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$3.72M | -4.56 | -34.06% | ― | -100.00% | 65.85% | |
45 Neutral | C$30.71M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
41 Neutral | C$7.77M | -5.12 | 6239.15% | ― | ― | 48.94% |
* Healthcare Sector Average
TSE:NDAT
nDatalyze Corp
0.09
0.07
260.00%
TSE:ADK
Diagnos
0.26
-0.02
-5.56%
TSE:VHI
Vitalhub
6.99
-2.65
-27.49%
TSE:AIDR
Rocket Doctor AI
0.62
0.19
42.53%
TSE:LITE
Spotlite360 Technologies
0.02
0.00
0.00%
TSE:UDOC
UniDoc Health Corp
0.09
-0.23
-71.88%
nDatalyze Corp Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
nDatalyze Joins Semi-Annual Reporting Pilot as RTO and Sports Tech Project Advance
Positive
Mar 26, 2026
nDatalyze Corp. plans to shift from quarterly to semi-annual financial reporting under the Canadian Securities Administrators’ pilot program, a move it says will cut compliance costs and free management to focus on its core AI-powered mental...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
nDatalyze Details Financing and Share Structure for PRISM Reverse Takeover
Neutral
Mar 12, 2026
nDatalyze Corp. has updated the terms and timeline of its proposed reverse takeover of PRISM Diversified Ltd., with the Definitive Agreement now expected by March 31, 2026. The deal is designed to create a resulting issuer heavily weighted toward ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
nDatalyze Plans Reverse Takeover by Alberta Mine-to-Metals Producer PRISM
Positive
Feb 19, 2026
nDatalyze Corp. has signed a non-binding memorandum of understanding with PRISM Diversified Ltd., an Alberta-based mine-to-metals producer, in a deal expected to result in a change of business and reverse takeover, pending regulatory and sharehold...
Business Operations and StrategyDelistings and Listing ChangesM&A Transactions
nDatalyze Ends FoodCo RTO, Refocuses on Hockey Analytics App and CSE Listing
Negative
Jan 22, 2026
nDatalyze Corp. has terminated its proposed reverse takeover transaction with a Vancouver-based private company referred to as FoodCo, citing ongoing delays and FoodCo’s default on certain terms of their binding memorandum of understanding s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.